Laekna's internal discovery focuses on obesity, metabolic diseases, oncology, and liver fibrosis. We are actively seeking global partners to accelerate the development and commercialization of these novel drug candidates.

LAE002 (afuresertib) Licensing Agreement China On 12 November,2025, Laekna entered into an exclusive licensing agreement with Qilu Pharma. Qilu Pharma is granted an exclusive license for research, development, and commercialization of LAE002 (afuresertib) in China.

LAE118（Novel PI3KαPan-Mutant Selective Inhibitor）Licensing Agreement Ex-China Region On 9 June, 2026, Laekna entered into an exclusive licensing agreement with Vasque Bio. Vasque Bio is granted, among other rights, an exclusive license in Ex-China Region to develop, manufacture and commercialize LAE118

Pursuant to the licensing agreement between Laekna and Novartis Pharma AG, Laekna is granted an exclusive license to develop, manufacture and commercialize LAE001, LAE002(afuresertib), LAE003 and LAE005 worldwide.

LAE102 U.S. Phase I 一一 Laekna has completed the study in collaboration with Eli Lilly and Company in March 2026, achieving positive topline results

Laekna is in active discussions with potential partners to accelerate the global development and commercialization of the drug candidates of the ActRII portfolio.

We’re also proactively pursuing innovative collaboration paradigms, such as co-development.

Laekna has entered into an exclusive licensing agreement with Qilu Pharma for LAE002 (afuresertib), an innovative drug candidate for the treatment of breast cancer in China. It marks the beginning of our commercial journey and paves a way for our drug candidates in the rich pipeline. More Details